FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2905275344> ?p ?o ?g. }

• W2905275344 endingPage "119" @default.
• W2905275344 startingPage "118" @default.
• W2905275344 abstract "Katzenschlager, R, Poewe, W, Rascol, O, et al. Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Neurol 2018; 17: 749– 759. Apomorphine is a dopamine agonist approved for the treatment of Parkinson's disease (PD) since 1993. Information about its benefits, either as intermittent subcutaneous injections or continuous infusion, has arisen from uncontrolled open-label studies that showed a marked reduction in OFF time,2 and decreased time with troublesome dyskinesias in the ON state.1, 2 However, until the article published by Katzenschlager and colleagues3 early this year, there was no clinical study that provided class 1 evidence for its efficacy and safety when used as continuous infusion. The TOLEDO3 study was the first double-blind, randomized clinical trial of apomorphine subcutaneous infusion conducted in PD patients. Patients with more than 3 years of disease duration and motor fluctuations not well controlled with oral or transdermal medical treatment, that consisted in at least ≥4 daily doses of levodopa, were included. The study design comprised 12 weeks with add-on apomorphine subcutaneous infusion or placebo, followed by an open-label 64 weeks of apomorphine treatment. One hundred seven patients were randomized, and most of them were hospitalized during the titration phase. Apomorphine dose was adjusted during the first 4 weeks, followed by an 8-week maintenance period (apomorphine dose: 3–8 mg/hr). Apomorphine subcutaneous infusion reduced OFF time (–2.47 vs. –0.58 hours), increased ON time without troublesome dyskinesia (2.77 vs. 0.80 hours), improved patient global impression of change, and allowed marked reductions in the l-dopa-equivalent dose. In addition, a significant increase in the number of patients with ≥2 hours’ reduction in OFF time was observed in the treatment group. Apomorphine infusion was well tolerated in most cases, and only mild-to-moderate adverse events were reported. Skin nodules (44%), nausea (22%), and somnolence (22%) were recorded as the most frequent adverse events, in line with previous reports.1, 2 Six patients from the apomorphine group had to withdraw from the study because of adverse events; 3 of them because of severe adverse events (symptomatic hypotension, myocardial infarction, and mild leukopenia). The TOLEDO study is somewhat limited by the unclear definition of “optimized medical treatment,” unlike previous studies on advanced medical therapies.4 However, it constitutes a strong evidence of treatment efficacy. l-odopa was used in clinical practice for a long time before the first randomized, double-blind, placebo-controlled trial (ELLDOPA) was published in 2004.5 However, the lack of evidence did not interfere with its massive use around the world. In contrast, although apomorphine has been used for almost 30 years, the lack of class 1 evidence has prevented for its generalized use. Hopefully, the TOLEDO study will encourage one to expand the use of this therapy worldwide, and will help this treatment to be considered a valid and competitive option for advanced therapy, and not as a last resort for patients who are not candidates for DBS or l-dopa/carbidopa intestinal gel. 1. Research Project: A. Conception, B. Organization, C. Execution; 2. Statistical Analysis: A. Design, B. Execution, C. Review and Critique; 3. Manuscript: A. Writing of the First Draft, B. Review and Critique. L.A.: 1A, 1B, 1C, 3A, 3B M.R.: 1A, 1B, 1C, 3A, 3B Ethical Compliance Statement: We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this work is consistent with those guidelines. The authors confirm that the approval of an institutional review board was not required for this work based on the submission type. Funding Sources and Conflicts of Interest: The authors report no sources of funding and no conflicts of interest. Financial Disclosures for previous 12 months: The authors declare that there are no disclosures to report." @default.
• W2905275344 created "2018-12-22" @default.
• W2905275344 creator A5052760777 @default.
• W2905275344 creator A5084319572 @default.
• W2905275344 date "2019-01-16" @default.
• W2905275344 modified "2023-10-16" @default.
• W2905275344 title "Apomorphine, More Evidence for An Old Drug: A Key for Therapy Generalization?" @default.
• W2905275344 cites W1533056363 @default.
• W2905275344 cites W2050731195 @default.
• W2905275344 cites W2109655049 @default.
• W2905275344 cites W2156377180 @default.
• W2905275344 cites W2884603783 @default.
• W2905275344 doi "https://doi.org/10.1002/mdc3.12717" @default.
• W2905275344 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6384177" @default.
• W2905275344 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30838309" @default.
• W2905275344 hasPublicationYear "2019" @default.
• W2905275344 type Work @default.
• W2905275344 sameAs 2905275344 @default.
• W2905275344 citedByCount "1" @default.
• W2905275344 countsByYear W29052753442021 @default.
• W2905275344 crossrefType "journal-article" @default.
• W2905275344 hasAuthorship W2905275344A5052760777 @default.
• W2905275344 hasAuthorship W2905275344A5084319572 @default.
• W2905275344 hasBestOaLocation W29052753441 @default.
• W2905275344 hasConcept C126322002 @default.
• W2905275344 hasConcept C137183658 @default.
• W2905275344 hasConcept C141071460 @default.
• W2905275344 hasConcept C142724271 @default.
• W2905275344 hasConcept C168563851 @default.
• W2905275344 hasConcept C204787440 @default.
• W2905275344 hasConcept C27081682 @default.
• W2905275344 hasConcept C2776390293 @default.
• W2905275344 hasConcept C2777525119 @default.
• W2905275344 hasConcept C2778258207 @default.
• W2905275344 hasConcept C2779134260 @default.
• W2905275344 hasConcept C2779734285 @default.
• W2905275344 hasConcept C2780304432 @default.
• W2905275344 hasConcept C2780405171 @default.
• W2905275344 hasConcept C42219234 @default.
• W2905275344 hasConcept C513476851 @default.
• W2905275344 hasConcept C71924100 @default.
• W2905275344 hasConceptScore W2905275344C126322002 @default.
• W2905275344 hasConceptScore W2905275344C137183658 @default.
• W2905275344 hasConceptScore W2905275344C141071460 @default.
• W2905275344 hasConceptScore W2905275344C142724271 @default.
• W2905275344 hasConceptScore W2905275344C168563851 @default.
• W2905275344 hasConceptScore W2905275344C204787440 @default.
• W2905275344 hasConceptScore W2905275344C27081682 @default.
• W2905275344 hasConceptScore W2905275344C2776390293 @default.
• W2905275344 hasConceptScore W2905275344C2777525119 @default.
• W2905275344 hasConceptScore W2905275344C2778258207 @default.
• W2905275344 hasConceptScore W2905275344C2779134260 @default.
• W2905275344 hasConceptScore W2905275344C2779734285 @default.
• W2905275344 hasConceptScore W2905275344C2780304432 @default.
• W2905275344 hasConceptScore W2905275344C2780405171 @default.
• W2905275344 hasConceptScore W2905275344C42219234 @default.
• W2905275344 hasConceptScore W2905275344C513476851 @default.
• W2905275344 hasConceptScore W2905275344C71924100 @default.
• W2905275344 hasIssue "2" @default.
• W2905275344 hasLocation W29052753441 @default.
• W2905275344 hasLocation W29052753442 @default.
• W2905275344 hasLocation W29052753443 @default.
• W2905275344 hasLocation W29052753444 @default.
• W2905275344 hasOpenAccess W2905275344 @default.
• W2905275344 hasPrimaryLocation W29052753441 @default.
• W2905275344 hasRelatedWork W140228277 @default.
• W2905275344 hasRelatedWork W1988989314 @default.
• W2905275344 hasRelatedWork W2024262327 @default.
• W2905275344 hasRelatedWork W2395410659 @default.
• W2905275344 hasRelatedWork W2411986191 @default.
• W2905275344 hasRelatedWork W2499182018 @default.
• W2905275344 hasRelatedWork W2726291975 @default.
• W2905275344 hasRelatedWork W2750516584 @default.
• W2905275344 hasRelatedWork W2923604435 @default.
• W2905275344 hasRelatedWork W4366724305 @default.
• W2905275344 hasVolume "6" @default.
• W2905275344 isParatext "false" @default.
• W2905275344 isRetracted "false" @default.
• W2905275344 magId "2905275344" @default.
• W2905275344 workType "article" @default.